Skip to main content
Erschienen in: Archives of Dermatological Research 6/2005

01.12.2005 | Original Paper

Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma

verfasst von: Mizuki Yamada, Koichi Yanaba, Kazuhiko Takehara, Shinichi Sato

Erschienen in: Archives of Dermatological Research | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Although several molecules have been evaluated as tumor markers of malignant melanoma (MM) progression, there are few available markers sensitive enough to detect recurrence or metastasis. The objective of the present study was to determine clinical significance of serum soluble adhesion molecules in the monitoring of progression in patients with MM. Serum levels of soluble L-selectin (sL-selectin), sE-selectin, sP-selectin, and soluble intercellular adhesion molecule-1 (sICAM-1) were determined by ELISA in 57 MM patients. In a retrospective longitudinal study, nine serum samples from two MM patients were analyzed during a follow-up period of 4.0 and 4.3 years, respectively. Serum sICAM-1 levels in MM patients were significantly higher than those in healthy controls and tended to be elevated as the disease stage progressed. In contrast, serum sL-selectin levels were significantly lower in MM patients compared to healthy controls and tended to decrease as the disease stage progressed. There was no significant difference in serum sE-selectin and sP-selectin levels between MM patients and normal control. In a longitudinal study, increased sICAM-1 and decreased sL-selectin levels were generally associated with the progression of MM. These results suggest that monitoring both sICAM-1 and sL-selectin is available to evaluate the progression of MM.
Literatur
1.
Zurück zum Zitat Adams DH, Mainolfi E, Elias E et al (1993) Detection of circulating intercellular adhesion molecule-1 after liver transplantation—evidence of local release within the liver during graft rejection. Transplantation 55:83–87PubMedCrossRef Adams DH, Mainolfi E, Elias E et al (1993) Detection of circulating intercellular adhesion molecule-1 after liver transplantation—evidence of local release within the liver during graft rejection. Transplantation 55:83–87PubMedCrossRef
2.
Zurück zum Zitat Altomonte M, Colizzi F, Esposito G, Maio M (1992) Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 327:959PubMed Altomonte M, Colizzi F, Esposito G, Maio M (1992) Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 327:959PubMed
3.
Zurück zum Zitat Banks RE, Gearing AJ, Hemingway IK et al (1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68:122–124PubMed Banks RE, Gearing AJ, Hemingway IK et al (1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68:122–124PubMed
4.
Zurück zum Zitat Becker JC, Dummer R, Hartmann AA et al (1991) Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 147:4398–4401PubMed Becker JC, Dummer R, Hartmann AA et al (1991) Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 147:4398–4401PubMed
5.
Zurück zum Zitat Fortis C, Galli L, Consogno G et al (1995) Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. Clin Immunol Immunopathol 76:142–147CrossRefPubMed Fortis C, Galli L, Consogno G et al (1995) Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. Clin Immunol Immunopathol 76:142–147CrossRefPubMed
6.
Zurück zum Zitat Harning R, Mainolfi E, Bystryn JC et al (1991) Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51:5003–5005PubMed Harning R, Mainolfi E, Bystryn JC et al (1991) Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51:5003–5005PubMed
7.
Zurück zum Zitat Hasegawa M, Takata M, Hatta N et al (1997) Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7:243–251PubMed Hasegawa M, Takata M, Hatta N et al (1997) Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7:243–251PubMed
8.
Zurück zum Zitat Haznedaroglu IC, Benekli M, Ozcebe O et al (2000) Serum L-selectin and P-selectin levels in lymphomas. Haematologia (Budap) 30:27–30CrossRef Haznedaroglu IC, Benekli M, Ozcebe O et al (2000) Serum L-selectin and P-selectin levels in lymphomas. Haematologia (Budap) 30:27–30CrossRef
9.
Zurück zum Zitat Hirai S, Kageshita T, Kimura T et al (1997) Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58–62PubMedCrossRef Hirai S, Kageshita T, Kimura T et al (1997) Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58–62PubMedCrossRef
10.
Zurück zum Zitat Izycka A, Jablonska E, Izycki T, Chyczewska E (2002) Expression of adhesion molecules LFA-1 and L-selectin on PMN and level of soluble sE-selectin and sL-selectin in the serum of patients with small cell lung cancer. Pneumonol Alergol Pol 70:403–408PubMed Izycka A, Jablonska E, Izycki T, Chyczewska E (2002) Expression of adhesion molecules LFA-1 and L-selectin on PMN and level of soluble sE-selectin and sL-selectin in the serum of patients with small cell lung cancer. Pneumonol Alergol Pol 70:403–408PubMed
11.
Zurück zum Zitat Kageshita T, Yoshii A, Kimura T et al (1993) Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 53:4927–4932PubMed Kageshita T, Yoshii A, Kimura T et al (1993) Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 53:4927–4932PubMed
12.
Zurück zum Zitat Leeuwenberg JF, Smeets EF, Neefjes JJ et al (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549PubMed Leeuwenberg JF, Smeets EF, Neefjes JJ et al (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549PubMed
13.
Zurück zum Zitat Lynch DF Jr, Hassen W, Clements MA et al (1997) Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 32:214–220CrossRefPubMed Lynch DF Jr, Hassen W, Clements MA et al (1997) Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 32:214–220CrossRefPubMed
14.
Zurück zum Zitat Nakatsura T, Kageshita T, Ito S et al (2004) Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10:6612–6621CrossRefPubMed Nakatsura T, Kageshita T, Ito S et al (2004) Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10:6612–6621CrossRefPubMed
15.
Zurück zum Zitat Olejnik I (1999) Serum soluble L-selectin in childhood acute lymphoblastic leukemia. Pediatr Int 41:246–248CrossRefPubMed Olejnik I (1999) Serum soluble L-selectin in childhood acute lymphoblastic leukemia. Pediatr Int 41:246–248CrossRefPubMed
16.
Zurück zum Zitat Schadendorf D, Diehl S, Zuberbier T et al (1996) Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 192:89–93PubMed Schadendorf D, Diehl S, Zuberbier T et al (1996) Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 192:89–93PubMed
17.
Zurück zum Zitat Scheibenbogen C, Keilholz U, Meuer S et al (1993) Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 54:494–498PubMedCrossRef Scheibenbogen C, Keilholz U, Meuer S et al (1993) Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 54:494–498PubMedCrossRef
18.
Zurück zum Zitat Tedder TF, Li X, Steeber DA (1999) The selectins and their ligands: adhesion molecules of the vasculature. Adv Mol Cell Biol 28:65–111CrossRef Tedder TF, Li X, Steeber DA (1999) The selectins and their ligands: adhesion molecules of the vasculature. Adv Mol Cell Biol 28:65–111CrossRef
19.
Zurück zum Zitat Tsujisaki M, Imai K, Hirata H et al (1991) Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol 85:3–8PubMedCrossRef Tsujisaki M, Imai K, Hirata H et al (1991) Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol 85:3–8PubMedCrossRef
20.
Zurück zum Zitat Tu L, Poe JC, Kadono T et al (2002) A functional role for circulating mouse L-selectin in regulating leukocyte/endothelial cell interactions in vivo. J Immunol 169:2034–2043PubMed Tu L, Poe JC, Kadono T et al (2002) A functional role for circulating mouse L-selectin in regulating leukocyte/endothelial cell interactions in vivo. J Immunol 169:2034–2043PubMed
21.
Zurück zum Zitat Yasasever V, Tas F, Duranyildiz D et al (2000) Serum levels of the soluble adhesion molecules in patients with malignant melanoma. Pathol Oncol Res 6:42–45PubMedCrossRef Yasasever V, Tas F, Duranyildiz D et al (2000) Serum levels of the soluble adhesion molecules in patients with malignant melanoma. Pathol Oncol Res 6:42–45PubMedCrossRef
22.
Zurück zum Zitat Zetterberg E, Richter J (1993) Correlation between serum level of soluble L-selectin and leukocyte count in chronic myeloid and lymphocytic leukemia and during bone marrow transplantation. Eur J Haematol 51:113–119PubMedCrossRef Zetterberg E, Richter J (1993) Correlation between serum level of soluble L-selectin and leukocyte count in chronic myeloid and lymphocytic leukemia and during bone marrow transplantation. Eur J Haematol 51:113–119PubMedCrossRef
Metadaten
Titel
Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma
verfasst von
Mizuki Yamada
Koichi Yanaba
Kazuhiko Takehara
Shinichi Sato
Publikationsdatum
01.12.2005
Verlag
Springer-Verlag
Erschienen in
Archives of Dermatological Research / Ausgabe 6/2005
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-005-0605-5

Weitere Artikel der Ausgabe 6/2005

Archives of Dermatological Research 6/2005 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.